Kedia Saurabh, Gunjan Deepak, Sonika Ujjwal, Mahapatra Soumya Jagannath, Nayak Baibaswata, Kaur Harpreet, Acharya Subrat Kumar
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India.
Dig Dis Sci. 2017 Apr;62(4):1058-1066. doi: 10.1007/s10620-017-4461-x. Epub 2017 Jan 27.
Hepatitis E virus (HEV) is a global disease and an important cause of acute liver failure (ALF) in the Indian subcontinent. The aim of this study was to assess the differences in the course of HEV-ALF as compared to other etiologies of ALF.
We compared the clinical course, complications, and outcomes of HEV-ALF with other etiologies. We assessed the prognostic factors and compared existing prognostic scores in HEV-ALF patients.
One thousand four hundred and sixty-two ALF patients were evaluated between January 1986 and December 2015. HEV was the etiology of ALF in 419 (28.7%) cases, whereas non-A non-E hepatitis, HBV and anti-tuberculosis therapy (ATT) were the etiologies in 527 (36.0%), 128 (8.8%), and 103 (7.0%) cases, respectively. The frequency of cerebral edema in HEV-ALF (41.3%) was lower than that in non-A non-E ALF (52.9%; P < 0.001) and HBV-ALF (52.8%; P = 0.024). Infection and seizures were significantly less in patients with HEV-ALF compared to non-A non-E and HBV-ALF (P = 0.038 and 0.022, respectively). The survival of HEV-ALF patients was significantly better (55.1%, P < 0.001) than patients of other etiologies-including ATT (30.0%), non-A non-E (38.1%) and HBV (35.9%). In HEV-ALF patients, age, female sex, cerebral edema, prothrombin time >60 s, infection, and total bilirubin were observed as independent predictors of outcome on multivariate logistic regression analysis. Model for end-stage liver disease, acute liver failure study group model and King's College Hospital criteria had poor discriminative accuracy for outcome (area under receiver operator characteristic curve 0.63-0.64) in HEV-ALF.
Hepatitis E virus-associated ALF has a better outcome than ALF of other etiologies.
戊型肝炎病毒(HEV)是一种全球性疾病,也是印度次大陆急性肝衰竭(ALF)的重要病因。本研究旨在评估与其他病因所致的ALF相比,戊型肝炎病毒相关性急性肝衰竭(HEV-ALF)病程的差异。
我们比较了HEV-ALF与其他病因所致ALF的临床病程、并发症及转归情况。我们评估了预后因素,并比较了HEV-ALF患者现有的预后评分。
1986年1月至2015年12月期间,共评估了1462例ALF患者。419例(28.7%)患者的病因是HEV,而527例(36.0%)、128例(8.8%)和103例(7.0%)患者的病因分别是非甲非戊型肝炎、乙肝病毒(HBV)和抗结核治疗(ATT)。HEV-ALF患者中脑水肿的发生率(41.3%)低于非甲非戊型ALF患者(52.9%;P<0.001)和HBV-ALF患者(52.8%;P=0.024)。与非甲非戊型和HBV-ALF患者相比,HEV-ALF患者感染和癫痫发作的发生率显著更低(分别为P=0.038和0.022)。HEV-ALF患者的生存率(55.1%,P<0.001)显著高于其他病因的患者,包括ATT(30.0%)、非甲非戊型(38.1%)和HBV(35.9%)。在HEV-ALF患者中,多因素逻辑回归分析显示年龄、女性、脑水肿、凝血酶原时间>60秒、感染和总胆红素是预后的独立预测因素。终末期肝病模型、急性肝衰竭研究组模型和国王学院医院标准对HEV-ALF患者预后的判别准确性较差(受试者工作特征曲线下面积为0.63-0.64)。
戊型肝炎病毒相关性急性肝衰竭比其他病因所致的急性肝衰竭预后更好。